权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Training Program in Basic Cancer Research

基础癌症研究培训计划

基本信息

批准号：
10654720
负责人：
Alessandro Gardini
金额：
$ 38.95万
依托单位：
WISTAR INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
1976
资助国家：
美国
起止时间：
1976-07-01 至 2027-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10654720
关键词：
Basic Cancer Research Training Programs

项目摘要

Project Summary The overarching goal of this longstanding “Training Program in Basic Cancer Research” is to provide the fundamental skills necessary for our trainees to succeed in outstanding careers in biomedical cancer research. Toward that goal we provide them with superior training in the conduct of cutting edge research, combined with a deep appreciation of the clinical challenges that doctors and patients face. To achieve this goal, we have created a unique Training program, now entering its 45th year, entitled the Training Program in Basic Cancer Research (TP-BCR). Support is requested for five postdoctoral fellows, and three predoctoral fellows from the University of Pennsylvania Perelman School of Medicine, program in Biomedical Graduate Studies. Located at the heart of the University of Pennsylvania campus, Wistar offers a superb research environment, recently rated “Exceptional” at the most recent CCSG renewal in 2018. We have crafted a training program that combines unique sub-programs entitled “Bench to Bedside Training” and a “Science Entrepreneurs” program, thus offering our trainees exposure to clinicians and clinical problems in cancer research, unique insight into the business of science and intellectual property, and a robust curriculum that includes workshops in teaching, writing, and grant preparation. Our 26 faculty mentors tackle diverse questions in cancer, most have long-standing successful training records, and all are well-funded, with an average of $890,000/year/mentor (DC). Our current trainee pool consists of 79 trainees, which includes 24 predoctoral trainees (13 TGE) and 55 postdoctoral trainees (20 TGE). There is an average of four TGE applicants for each proffered slot, thus allowing us to place the most highly qualified trainees in this program. All slots have been continuously filled for the entire funding period, and our trainees continue to be highly productive, with 4.7 manuscripts and 2 first author manuscripts per trainee averaged in the past three cycles, and 98% of our trainees continuing in research-related or research-intensive careers. Taken together, this long-standing program, which is the only T32 centered at The Wistar Institute, will provide the fundamental skills necessary for our trainees to flourish in successful independent careers in cancer research.

项目概要这个长期的“基础癌症研究培训计划”的总体目标是提供我们的学员在生物医学癌症领域取得杰出职业生涯所需的基本技能研究。为了实现这一目标，我们为他们提供尖端培训研究，结合对医生和患者面临的临床挑战的深刻理解。到为了实现这一目标，我们创建了一个独特的培训计划，现已进入第 45 个年头，名为基础癌症研究培训计划 (TP-BCR)。请求支持5名博士后宾夕法尼亚大学佩雷尔曼医学院的研究员和三名博士前研究员，生物医学研究生课程。位于宾夕法尼亚大学校园的中心， Wistar 提供一流的研究环境，最近在最近的 CCSG 上被评为“杰出” 2018 年更新。我们精心设计了一个培训计划，结合了题为“Bench 床边培训”和“科学企业家”计划，从而使我们的学员能够接触到临床医生和癌症研究中的临床问题，对科学和商业的独特见解知识产权，以及包括教学、写作和资助研讨会在内的强大课程准备。我们的 26 名教师导师致力于解决癌症领域的各种问题，其中大多数都长期存在成功的培训记录，并且资金充足，平均每年每位导师 (DC) 为 890,000 美元。我们的目前的学员库由 79 名学员组成，其中包括 24 名博士前学员（13 名 TGE）和 55 名博士后实习生（20 TGE）。每个提供的席位平均有四名 TGE 申请者，因此使我们能够将最优秀的学员安置在该计划中。所有槽位均已连续整个资助期间都已满员，我们的学员继续保持高生产力，共收到 4.7 份稿件在过去的三个周期中，每位学员平均有 2 篇第一作者手稿，并且我们 98% 的学员继续从事研究相关或研究密集型职业。综合起来，这个长期存在的项目是唯一以 Wistar 学院为中心的 T32 项目，将提供基本技能对于我们的学员在癌症研究领域取得成功的独立职业生涯来说这是必要的。

项目成果

期刊论文数量（75）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.

使用 INO-4800 和 INO-4802 的初免加强疫苗接种方案可增强和扩大非人灵长类动物针对 SARS-CoV-2 的免疫反应。

DOI：
10.1016/j.vaccine.2022.03.060
发表时间：
2022-05-09
期刊：
Vaccine
影响因子：
5.5
作者：
Walters JN;Schouest B;Patel A;Reuschel EL;Schultheis K;Parzych E;Maricic I;Gary EN;Purwar M;Andrade VM;Doan A;Elwood D;Eblimit Z;Nguyen B;Frase D;Zaidi FI;Kulkarni A;Generotti A;Joseph Kim J;Humeau LM;Ramos SJ;Smith TRF;Weiner DB;Broderick KE
通讯作者：
Broderick KE

Point mutations of the adenovirus major late promoter with different transcriptional efficiencies in vitro.

腺病毒主要晚期启动子的点突变在体外具有不同的转录效率。